VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults
May 15th 2008Drug InformationADHD
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. “Adults with ADHD often find it challenging to focus and organize during the day.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
